Chemobrain in Breast Cancer: Mechanisms, Clinical Manifestations, and Potential Interventions

Giovana R. Onzi (), Nathalia D’Agustini, Solange C. Garcia, Silvia S. Guterres, Paula R. Pohlmann, Daniela D. Rosa and Adriana R. Pohlmann ()
Additional contact information
Giovana R. Onzi: Universidade Federal do Rio Grande do Sul
Nathalia D’Agustini: Programa de Pós-Graduação em Patologia da Universidade Federal de Ciências da Saúde de Porto Alegre
Solange C. Garcia: Universidade Federal do Rio Grande do Sul
Silvia S. Guterres: Universidade Federal do Rio Grande do Sul
Paula R. Pohlmann: MedStar Georgetown University Hospital
Daniela D. Rosa: Programa de Pós-Graduação em Patologia da Universidade Federal de Ciências da Saúde de Porto Alegre
Adriana R. Pohlmann: Universidade Federal do Rio Grande do Sul

Drug Safety, 2022, vol. 45, issue 6, No 2, 621 pages

Abstract: Abstract Among the potential adverse effects of breast cancer treatment, chemotherapy-related cognitive impairment (CRCI) has gained increased attention in the past years. In this review, we provide an overview of the literature regarding CRCI in breast cancer, focusing on three main aspects. The first aspect relates to the molecular mechanisms linking individual drugs commonly used to treat breast cancer and CRCI, which include oxidative stress and inflammation, reduced neurogenesis, reduced levels of specific neurotransmitters, alterations in neuronal dendrites and spines, and impairment in myelin production. The second aspect is related to the clinical characteristics of CRCI in patients with breast cancer treated with different drug combinations. Data suggest the incidence rates of CRCI in breast cancer vary considerably, and may affect more than 50% of treated patients. Both chemotherapy regimens with or without anthracyclines have been associated with CRCI manifestations. While cross-sectional studies suggest the presence of symptoms up to 20 years after treatment, longitudinal studies confirm cognitive impairments lasting for at most 4 years after the end of chemotherapy. The third and final aspect is related to possible therapeutic interventions. Although there is still no standard of care to treat CRCI, several pharmacological and non-pharmacological approaches have shown interesting results. In summary, even if cognitive impairments derived from chemotherapy resolve with time, awareness of CRCI is crucial to provide patients with a better understanding of the syndrome and to offer them the best care directed at improving quality of life.

Date: 2022
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-022-01182-3 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:45:y:2022:i:6:d:10.1007_s40264-022-01182-3

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-022-01182-3

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().